Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26

Eris Lifesciences to leverage Novo Nordisk’s exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused products planned for commercialisation in FY26

​Eris Lifesciences to leverage Novo Nordisk’s exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused products planned for commercialisation in FY26